Recently, a combination of two targeted therapies for advanced ovarian cancer has been approved that includes a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody and poly [adenosine diphosphate (ADP)-ribose] polymerase (PARP) inhibitor. Here, VEGFA is linked to ovarian cancer.